| |
Newsroom /
Military
/
Military
/
Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020
Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020
The Prostate Cancer Therapeutics Market was driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy
Hyderabad,
AP,
India
(prbd.net)
23/11/2010
GlobalData analysis finds that the US prostate cancer therapeutics market is attractive and is primarily driven by the growth in the hormone-refractory prostate cancer therapeutics market. The growth in the number of total patients receiving treatment and increase in the annual cost of hormone-refractory prostate cancer therapy is expected to offset the impact of generic erosion in hormone-dependent prostate cancer therapy. The patient volume was driven by growth in treatment usage patterns such as diseased population, treatment seeking population, diagnosis population and prescription population. The annual cost of prostate cancer therapy was driven by the launch of new therapies such as Taxotere (docetaxel), Provenge (sipuleucel-T) and Jevtana (cabazitaxel).
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Prostate-Cancer--US-Drug-Forecasts-and-Treatment-Analysis-to-2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Hormone therapy using combination of hormone therapies such as LHRH agonists and androgen receptor antagonists is a prominent treatment regime. Taxotere is the current standard of care for patients that stop responding to hormone therapy. The introduction of new therapies for metastatic prostate cancer is expected to expand the market further.
In 2009, the US was the leading market in the global prostate cancer therapeutics market with an estimated market share of approximately 59%.
In 2009, Taxotere was the leading drug with approximate sales worth $578.9m and a market share of 32% of the prostate cancer therapeutics market in US. Casodex (bicalutamide) and Zoladex (goserelin) were the most used hormone therapies and together accounted for approximately 47% of the total prostate cancer therapeutics market in the US. The impact of generic competition for Casodex in 2008 and Taxotere in 2011 is expected to partially offset the growth in revenue due to new product launched in the forecast period 2009 to 2020.
GlobalData, the industry analysis specialist, has released its new report, “Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the US prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the US prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the US prostate cancer therapeutics market, highlighting the opportunity for future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Prostate-Cancer--US-Drug-Forecasts-and-Treatment-Analysis-to-2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|